Comparison of Filgrastim and Lenograstim in Pediatric Solid Tumors

REFERENCES

• Sung L, Nathan PC, Lange B, Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22:3350–3356.
   PubMed Web of Science ®Google Scholar
• Wittman B, Horan J, Lyman GH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2006;32:289–303.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205.
   PubMed Web of Science ®Google Scholar
• Agrawal AK, Hastings AC, Feusner J. Hematologic supportive care for children with cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practise of Pediatric Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:1152–1189.
   Google Scholar
• Holloway CJ. In vitro stability and activity studies. Int J Hematol. 1996;64(Suppl 2):3–4.
   Google Scholar
• Saunders G. G-CSFs in daily pharmaceutical practice. Aten Farm. 2001;3:266–270.
   Google Scholar
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12:2471–2508.
   PubMed Web of Science ®Google Scholar
• Febril Nötropeni Çalışma Grubu. Febril nötropenik hastalarda tanı ve tedavi klavuzu. Flora. 2004;9:5–28.
   Google Scholar
• Barkatz JL. Growth factors: which equivalence? Therapeutique et Pratique Hospitaliere. 1997;44:5–7.
   Google Scholar
• Hasegawa M. A thermodynamic model for denaturation of granulocyte colony-stimulating factor: O-linked sugar chain suppresses not the triggering deprotonation but the succeeding denaturation. Biochim Biophys Acta. 1993;1203:295–297.
   PubMedGoogle Scholar
• Kishita M, Motojima H, Oheda M. Stability of granulocyte colony sitimulating factor in serum. Clin Rep. 1992;26:221–224.
   Google Scholar
• Oh-eda M, Hasegawa M, Hattori K, O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem. 1990;265:11432–11435.
   PubMed Web of Science ®Google Scholar
• Löwenberg B. Proliferative activity of rG-CSFsin cell line bioassays. Int J Hematol. 1996;64(Suppl 2):13–14.
   Google Scholar
• Azzara A, Carulli G, Cecconi N. Effects of lenograstim and filgrastim on neutrophil chemotaxis in patients undergoing chemotherapy. Hematologica. 1999;84:SS1084.
   Google Scholar
• Decleva E, Cramer R, Zabucchi G. Glycosylation improves the priming effect exerted by recombinant human granulocyte colony-stimulating factor (lenograstim) on human neutrophil superoxide production. Int J Tissue React. 1995;17:191–198.
   PubMedGoogle Scholar
• Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer. 1994;30(Suppl 3):S12–S14.
   Google Scholar
• Ribeiro D, Veldwijk MR, Benner A, Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion. 2007;47:969–980.
   PubMed Web of Science ®Google Scholar
• Ria R, Gasparre T, Mangialardi G, Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant. 2010;45:277–281.
   PubMed Web of Science ®Google Scholar
• Hüttmann A, Schirsafi K, Seeber S, Bojko P. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol. 2005;131:152–156.
   PubMed Web of Science ®Google Scholar
• Bönig H, Silbermann S, Weller S, Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)–results of a prospective randomized monocentre study. Bone Marrow Transplant. 2001;28:259–264.
   PubMed Web of Science ®Google Scholar
• Watts MJ, Sullivan AM, Jamieson E, Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol. 1997;15:535–546.
   PubMed Web of Science ®Google Scholar
• Höglund M, Smedmyr B, Bengtsson M, Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers–a comparative study. Eur J Haematol. 1997;59:177–183.
   PubMed Web of Science ®Google Scholar
• de Arriba F, Lozano ML, Ortuño F, Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells. Br JHaematol. 1997;96:418–420.
   PubMed Web of Science ®Google Scholar
• Kopf B, De Giorgi U, Vertogen B, A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant. 2006;38:407–412.
   PubMed Web of Science ®Google Scholar
• Fischer JC, Frick M, Wassmuth R, Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol. 2005;130:740–746.
   PubMed Web of Science ®Google Scholar
• Ataergin S, Arpaci F, Turan M, Reduced dose of lenograstim is as efficacious as standard dose offilgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol. 2008;83:644–648.
   PubMed Web of Science ®Google Scholar
• Kim IH, Park SK, Suh OK, Oh JM. Comparison of lenograstim and filgrastim onhaematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opin. 2003;19:753–759.
   PubMed Web of Science ®Google Scholar